RxDoctor Payments Data

Anita Szady, MD

Advanced Heart Failure and Transplant Cardiology · Larkspur, CANPI 1285722686

Payments from drug & device makers

$510in general payments, 2019–2025

Across 17 payments — averaging $29.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$112
  • Actelion Pharmaceuticals US, Inc.$101
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$73
  • AstraZeneca$56
  • Boston Scientific$42
  • Novartis$33
  • plus $94 from 5 others

What the payments were for

  • Food & beverage$46892%
  • Education$428%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$510 in reported general payments places this provider in the 5th percentile of 111 advanced heart failure and transplant cardiology providers in California.

See all advanced heart failure and transplant cardiology providers in California

Medicare billing

Part B allowed, 2024
$321,260
Medicare patients
1,268
Services billed
4,337

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis68$1,813,395
VyndaqelTafamidis Meglumine24$806,935
EntrestoSacubitril/Valsartan627$690,704
EliquisApixaban254$316,184
FarxigaDapagliflozin Propanediol229$217,362
CamzyosMavacamten23$184,205
JardianceEmpagliflozin165$150,380
XareltoRivaroxaban56$75,983
Repatha SureclickEvolocumab48$55,098
DapagliflozinDapagliflozin Propanediol22$16,341
Metoprolol Succinate437$7,256
Dabigatran EtexilateDabigatran Etexilate Mesylate23$5,323
Atorvastatin Calcium429$4,458
Ezetimibe129$4,017
Diltiazem 24hr Er (Cd)Diltiazem Hcl38$3,890

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Vyndaqel, Eliquis$16$2,936,514346 claims
NovartisEntresto$33$690,704627 claims
AstraZenecaFarxiga$56$217,362229 claims
Johnson & JohnsonXarelto$17$75,98356 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 111 advanced heart failure and transplant cardiology providers in California.

Other advanced heart failure and transplant cardiology in Larkspur

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →